Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PPARG_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PPARG_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPARG_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPARG_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PPARG_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010038112 | Thyroid | PTC | response to metal ion | 157/5968 | 373/18723 | 1.80e-05 | 1.86e-04 | 157 |
GO:0071453112 | Thyroid | PTC | cellular response to oxygen levels | 83/5968 | 177/18723 | 2.01e-05 | 2.04e-04 | 83 |
GO:190121518 | Thyroid | PTC | negative regulation of neuron death | 95/5968 | 208/18723 | 2.01e-05 | 2.04e-04 | 95 |
GO:000600615 | Thyroid | PTC | glucose metabolic process | 90/5968 | 196/18723 | 2.54e-05 | 2.50e-04 | 90 |
GO:20007566 | Thyroid | PTC | regulation of peptidyl-lysine acetylation | 36/5968 | 63/18723 | 2.98e-05 | 2.86e-04 | 36 |
GO:0046939110 | Thyroid | PTC | nucleotide phosphorylation | 52/5968 | 101/18723 | 3.25e-05 | 3.08e-04 | 52 |
GO:004320015 | Thyroid | PTC | response to amino acid | 58/5968 | 116/18723 | 3.59e-05 | 3.36e-04 | 58 |
GO:004544418 | Thyroid | PTC | fat cell differentiation | 102/5968 | 229/18723 | 3.66e-05 | 3.40e-04 | 102 |
GO:0009743113 | Thyroid | PTC | response to carbohydrate | 111/5968 | 253/18723 | 3.77e-05 | 3.48e-04 | 111 |
GO:00063525 | Thyroid | PTC | DNA-templated transcription, initiation | 63/5968 | 130/18723 | 5.72e-05 | 5.05e-04 | 63 |
GO:000920120 | Thyroid | PTC | ribonucleoside triphosphate biosynthetic process | 40/5968 | 74/18723 | 6.30e-05 | 5.53e-04 | 40 |
GO:001082210 | Thyroid | PTC | positive regulation of mitochondrion organization | 40/5968 | 74/18723 | 6.30e-05 | 5.53e-04 | 40 |
GO:000915224 | Thyroid | PTC | purine ribonucleotide biosynthetic process | 78/5968 | 169/18723 | 6.88e-05 | 6.01e-04 | 78 |
GO:005109016 | Thyroid | PTC | regulation of DNA-binding transcription factor activity | 178/5968 | 440/18723 | 7.63e-05 | 6.54e-04 | 178 |
GO:0034284112 | Thyroid | PTC | response to monosaccharide | 99/5968 | 225/18723 | 8.42e-05 | 7.03e-04 | 99 |
GO:0006165110 | Thyroid | PTC | nucleoside diphosphate phosphorylation | 50/5968 | 99/18723 | 8.68e-05 | 7.22e-04 | 50 |
GO:0009266111 | Thyroid | PTC | response to temperature stimulus | 81/5968 | 178/18723 | 9.20e-05 | 7.63e-04 | 81 |
GO:1903578111 | Thyroid | PTC | regulation of ATP metabolic process | 45/5968 | 87/18723 | 9.31e-05 | 7.71e-04 | 45 |
GO:0034612111 | Thyroid | PTC | response to tumor necrosis factor | 109/5968 | 253/18723 | 1.08e-04 | 8.69e-04 | 109 |
GO:0036294112 | Thyroid | PTC | cellular response to decreased oxygen levels | 74/5968 | 161/18723 | 1.23e-04 | 9.75e-04 | 74 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPARG | SNV | Missense_Mutation | | c.724C>G | p.Leu242Val | p.L242V | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-A2-A0YC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
PPARG | SNV | Missense_Mutation | rs140204299 | c.1154N>A | p.Arg385Gln | p.R385Q | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | rs777334819 | c.235N>A | p.Glu79Lys | p.E79K | P37231 | protein_coding | tolerated_low_confidence(0.26) | benign(0.039) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
PPARG | SNV | Missense_Mutation | | c.724C>G | p.Leu242Val | p.L242V | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-OL-A66H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | novel | c.489N>G | p.Phe163Leu | p.F163L | P37231 | protein_coding | deleterious(0) | possibly_damaging(0.535) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
PPARG | insertion | Frame_Shift_Ins | novel | c.549_550insA | p.Ser186LysfsTer2 | p.S186Kfs*2 | P37231 | protein_coding | | | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PPARG | insertion | Nonsense_Mutation | novel | c.64_65insTGTTAGTAATGTAGGGATG | p.Ser22LeufsTer5 | p.S22Lfs*5 | P37231 | protein_coding | | | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | | c.181N>C | p.Asp61His | p.D61H | P37231 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.969) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PPARG | SNV | Missense_Mutation | | c.1477N>T | p.Leu493Phe | p.L493F | P37231 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-G4-6307-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | SD |
PPARG | deletion | Frame_Shift_Del | | c.550delN | p.Ser186ValfsTer47 | p.S186Vfs*47 | P37231 | protein_coding | | | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | GTF505 | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | BENSULIDE | BENSULIDE | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135650496 | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | SHINPTEROCARPIN | SHINPTEROCARPIN | 20022509 |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | TREPROSTINIL | TREPROSTINIL | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | modulator | CHEMBL490029 | MK-0533 | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | DICHLOROPHEN | DICHLOROPHEN | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | FLUDIOXONIL | FLUDIOXONIL | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | ETHYL EICOSAPENTAENOIC ACID | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | AMORFRUTIN A | AMORFRUTIN A | 25938459 |